Home › Primary Ovarian Insufficiency › NCT06866119
Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency
Effects of Estrogen Replacement on Cardiometabolic Endpoints in Women With Primary Ovarian Insufficiency
Who can join
Ages 30 to 40 · Women · Healthy volunteers welcome
Full eligibility criteria
Inclusion criteria (I): * female sex * age 30-40 * CASE PARTICIPANTS ONLY: clinically documented POI diagnosis within 6 months * CASE PARTICIPANTS ONLY: planning to clinically initiate 100mcg transdermal 17beta-estradiol twice weekly and micro-ionized progesterone (either 100mg daily or 200mg cyclically) * CONTROL PARTICIPANTS ONLY: regular menstrual cycles every 21-35 days Exclusion criteria (E): * CASE PARTICIPANTS ONLY: genetic POI etiology * CASE PARTICIPANTS ONLY: any prior initiation of ERT * systemic estrogen, progesterone or testosterone therapy within the past 6 months (including contraception, except for locally acting intrauterine devices - IUDs) * lipid lowering therapy within the past 6 months * use of antihypertensive medication within the past 6 months * current treatment with prescription, systemic (oral, IV, or IM) steroids or anti-inflammatory/immune suppressant medical therapies (excluding topical therapies, UV therapy, ASA-derivative therapies, or NSAIDS) for autoimmune/inflammatory diseases (psoriasis, RA, IBD, lupus), post-transplant care, asthma, or pain syndromes * use of oral steroids or prescription oral anti-inflammatory/immune suppressant medication for \>7 days within the past 1 month * use of IV or IM steroids or IV or IM anti-inflammatory/immune suppressant medication within the past 3 months * self-reported history of breast and/or estrogen dependent malignancy * self-reported history of deep vein thromboembolism, pulmonary embolism or stroke * self-reported severe liver disease such as cirrhosis * self-reported hypercoagulable disorder * uncontrolled hypertension at baseline Visit #1- systolic blood pressure (SBP) ≥180 and/or diastolic blood pressure (DBP) ≥110 * tobacco use within 6 months * self-reported history of myocardial infarction, stroke, coronary revascularization or diabetes as a CVD risk equivalent * stable or unstable angina * self-reported history of heart failure * pregnancy or breastfeeding * concurrent enrollment in conflicting research study
About the study
The goal of this observational study is to study the effects of treating women with Primary Ovarian Insufficiency (POI) with estrogen replacement therapy to bolster the evidence backing cardiometabolic preventive care in women with POI. The main question it aims to answer is:
Does 6 months of estrogen replacement therapy for women with POI improved markers of heart health?
Women newly diagnosed with POI (within 6 months) who are planning to start estrogen replacement therapy from their clinical provider will undergo assessment of markers of heart health before and after 6 months of treatment. These markers will also be compared to those obtained from healthy women without POI.
Sponsor: Massachusetts General Hospital · Participants: 45 · Started: Jun 22, 2026
Contact the study team
- Lauren Maldonado, MD, MPH · Phone: 617-643-4420
- Markella V. Zanni, MD · Phone: 617-726-7948
Official record on ClinicalTrials.gov — NCT06866119
Locations in the U.S.
| Massachusetts | Massachusetts General Hospital, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.